Aptose Biosciences Inc (APTO) concluded trading on Wednesday at a closing price of $0.23, with 128.16 million shares of worth about $29.48 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -51.54% during that period and on February 12, 2025 the price saw a gain of about 27.04%. Currently the company’s common shares owned by public are about 60.18M shares, out of which, 56.51M shares are available for trading.
Stock saw a price change of 24.35% in past 5 days and over the past one month there was a price change of 8.18%. Year-to-date (YTD), APTO shares are showing a performance of 1.55% which decreased to -88.73% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $2.16 during that period. The average intraday trading volume for Aptose Biosciences Inc shares is 6.90 million. The stock is currently trading 17.91% above its 20-day simple moving average (SMA20), while that difference is up 12.13% for SMA50 and it goes to -55.67% lower than SMA200.
Aptose Biosciences Inc (NASDAQ: APTO) currently have 60.18M outstanding shares and institutions hold larger chunk of about 5.89% of that.
The stock has a current market capitalization of $13.77M and its 3Y-monthly beta is at 1.07. It has posted earnings per share of -$3.05 in the same period. It has Quick Ratio of 1.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APTO, volatility over the week remained 10.56% while standing at 8.33% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on October 19, 2020 offering an Overweight rating for the stock and assigned a target price of $10 to it. Coverage by Alliance Global Partners stated Aptose Biosciences Inc (APTO) stock as a Buy in their note to investors on September 22, 2020, suggesting a price target of $12 for the stock. On February 20, 2020, Maxim Group Initiated their recommendations, while on February 06, 2020, H.C. Wainwright Reiterated their ratings for the stock with a price target of $9. Stock get an Overweight rating from Piper Sandler on January 09, 2020.
